Precision medicine for advanced prostate cancer.

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Precision cancer medicine is revolutionizing cancer treatment by utilizing genomic profiling.
• Advanced prostate cancer management can benefit from tailored therapeutic strategies.
• Genomic profiling of tumors guides treatment decisions at the point-of-care.

Purpose of the Study:

• To review the potential and challenges of precision medicine in advanced prostate cancer.
• To explore how genomic profiling can inform treatment strategies for prostate cancer patients.
• To discuss the current landscape and future directions of precision oncology in prostate cancer.

Main Methods:

• Review of recent scientific literature on prostate cancer genomics.
• Analysis of genomic alterations in metastatic castration-resistant prostate cancer.
• Evaluation of liquid tumor profiling techniques, including circulating tumor cells and cell-free tumor DNA.

Main Results:

• Metastatic castration-resistant prostate cancer exhibits targetable genomic alterations.
• PARP-1 inhibition is a potential therapeutic strategy for specific genomic alterations in DNA repair pathways.
• Liquid tumor profiling shows promise for non-invasive cancer assessment in prostate cancer.

Conclusions:

• Precision medicine holds significant potential for impacting advanced prostate cancer care.
• Addressing scientific and clinical barriers is crucial for the widespread adoption of precision medicine.
• Genomic stratification and targeted therapies are key to advancing prostate cancer treatment.